Advanced Renal Cell Carcinoma: Incorporating Quality of Life into Treatment Sequencing

Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent therapies for advanced renal cell carcinoma (RCC). He explains that although maintaining disease control remains an important objective, treatment priorities often evolve in later lines of therapy to place greater emphasis on symptom management, preservation of daily functioning, and minimizing treatment-related toxicity. Dr. Pal describes how prior treatment experience, particularly tolerance to tyrosine kinase inhibitors, influences his therapeutic decision making after progression. He explains that patients who experience significant treatment-related adverse events may benefit from alternative therapies with more favorable tolerability profiles, while those unable to tolerate tyrosine kinase inhibitors may be considered for non-tyrosine kinase inhibitor options. Throughout the discussion, Dr. Pal emphasizes that quality-of-life considerations should be integrated into sequencing decisions, reinforcing the importance of individualizing treatment strategies to align with each patient's clinical status, treatment tolerance, and overall goals of care in advanced renal cell carcinoma.